

Marco Puzzoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/421436/publications.pdf>

Version: 2024-02-01

64

papers

882

citations

471509

17

h-index

526287

27

g-index

66

all docs

66

docs citations

66

times ranked

1676

citing authors

#	ARTICLE	IF	CITATIONS
1	Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer.. Journal of Clinical Oncology, 2022, 40, 182-182.	1.6	0
2	HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples. British Journal of Cancer, 2022, 126, 1783-1794.	6.4	12
3	Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients. Frontiers in Oncology, 2022, 12, 852583.	2.8	6
4	How to improve metastatic pancreatic ductal adenocarcinoma patientsâ€™ selection: Between clinical trials and the real-world. World Journal of Clinical Oncology, 2022, 13, 417-422.	2.3	0
5	Influence of type 2 diabetes mellitus and concomitant anti-diabetic medications in patients with metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e16301-e16301.	1.6	0
6	Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. European Journal of Cancer, 2022, 171, 232-241.	2.8	7
7	Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy.. Journal of Clinical Oncology, 2022, 40, 4153-4153.	1.6	0
8	Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Tumori, 2021, 107, 550-555.	1.1	5
9	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. Critical Reviews in Oncology/Hematology, 2021, 157, 103167.	4.4	30
10	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. Targeted Oncology, 2021, 16, 517-527.	3.6	7
11	Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 3577-3577.	1.6	2
12	Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. Clinical Colorectal Cancer, 2021, , .	2.3	0
13	BRCA-mutant pancreatic ductal adenocarcinoma. British Journal of Cancer, 2021, 125, 1321-1332.	6.4	15
14	Molecular-driven treatment for biliary tract cancer: the promising turning point. Expert Review of Anticancer Therapy, 2021, 21, 1253-1264.	2.4	0
15	Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Science, 2021, 112, 4819-4833.	3.9	4
16	Results of the observational prospective RealFLOT study. BMC Cancer, 2021, 21, 1086.	2.6	17
17	Cholangiocarcinoma: new perspectives for new horizons. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1367-1383.	3.0	13
18	Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2021, 25, 987-1005.	3.4	8

#	ARTICLE	IF	CITATIONS
19	Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients?. <i>Future Oncology</i> , 2020, 16, 4337-4339.	2.4	11
20	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492094669.	1.3	9
21	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1214.	3.7	26
22	From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. <i>Cancers</i> , 2020, 12, 1330.	3.7	7
23	Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4494.	4.1	24
24	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. <i>Targeted Oncology</i> , 2020, 15, 115-126.	3.6	15
25	Immune Checkpoint Inhibitors in the Treatment of HCC. <i>Frontiers in Oncology</i> , 2020, 10, 601240.	2.8	77
26	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. <i>European Journal of Cancer</i> , 2020, 133, 66-73.	2.8	19
27	Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 660-660.	1.6	3
28	Perioperative FLOT in resectable gastric cancer: Italian real-world data from the RealFLOT study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 300-300.	1.6	0
29	Perioperative FLOT in elderly patients with resectable gastric cancer: Subgroup analysis from the observational RealFLOT study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4548-4548.	1.6	0
30	Clustered protocadherins methylation alterations in cancer. <i>Clinical Epigenetics</i> , 2019, 11, 100.	4.1	33
31	Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine. <i>Annals of Oncology</i> , 2019, 30, iv63.	1.2	0
32	A new prognostic score for biliary tract cancer: a multicenter experience. <i>Annals of Oncology</i> , 2019, 30, iv92.	1.2	0
33	Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab. <i>Annals of Oncology</i> , 2019, 30, v226.	1.2	0
34	New therapeutic targets in pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2019, 81, 101926.	7.7	74
35	<p>Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2981-2988.	2.0	26
36	RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15663-e15663.	1.6	0

#	ARTICLE	IF	CITATIONS
37	BRAF-mutant colorectal cancer, a different breed evolving. Expert Review of Molecular Diagnostics, 2018, 18, 499-512.	3.1	19
38	The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome. Annals of Oncology, 2018, 29, viii264.	1.2	0
39	P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. Annals of Oncology, 2018, 29, v58-v59.	1.2	0
40	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: TheÂTOREADOR Study. Clinical Colorectal Cancer, 2018, 17, e601-e615.	2.3	18
41	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. Critical Reviews in Oncology/Hematology, 2017, 110, 106-116.	4.4	33
42	Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?. European Journal of Endocrinology, 2017, 177, 85-92.	3.7	23
43	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology, 2017, 115, 1-12.	4.4	26
44	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. British Journal of Cancer, 2017, 117, 315-321.	6.4	19
45	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. Scientific Reports, 2017, 7, 45703.	3.3	22
46	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	3.1	85
47	Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2017, 120, 13-21.	4.4	56
48	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 302 117, 1099-1104.	6.4	11
49	Management of breakthrough cancer pain in patients with oral mucositis. Annals of Oncology, 2017, 28, vi104.	1.2	0
50	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab. Annals of Oncology, 2017, 28, vi9-vi10.	1.2	0
51	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. Oncotarget, 2017, 8, 66699-66708.	1.8	11
52	The role of sidedness, EGFR gene copy number (GCN) and EGFR promoter methylation in RAS/BRAF wild type (WT) colorectal cancer (CRC) patients receiving irinotecan/cetuximab.. Journal of Clinical Oncology, 2017, 35, 628-628.	1.6	0
53	Prognostic neutrophil-to-lymphocyte ratio in head and neck cancer: A single center experience.. Journal of Clinical Oncology, 2017, 35, e17540-e17540.	1.6	0
54	Effective combinatorial immunotherapy for castration-resistant prostate cancer: new future chance?. Translational Cancer Research, 2017, 6, S1014-S1017.	1.0	0

#	ARTICLE	IF	CITATIONS
55	Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. Journal of Cardiovascular Medicine, 2016, 17, e12-e18.	1.5	78
56	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. Targeted Oncology, 2016, 11, 593-603.	3.6	14
57	REINVENT (REgorafenib traNslational eValuation angiogENesis proTocol). Annals of Oncology, 2016, 27, iv53.	1.2	0
58	Selection with a molecular Panel for Panitumumab Efficacy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER-PEAK). Annals of Oncology, 2016, 27, vi205.	1.2	0
59	Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management.. Journal of Clinical Oncology, 2016, 34, e15004-e15004.	1.6	0
60	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiALdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis.. Journal of Clinical Oncology, 2016, 34, e15116-e15116.	1.6	0
61	INTEGRATE phase II trial: regorafenib vs. placebo in pretreated metastatic gastric cancer patients—is there anything new?. Translational Cancer Research, 2016, 5, S1047-S1050.	1.0	0
62	Clinical Outcome of Patients With Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. Annals of Oncology, 2015, 26, vi50.	1.2	2
63	A single institution survey on prevalence and management of severe cancer pain in patients with cancer of different sites. Annals of Oncology, 2015, 26, vi116.	1.2	1
64	The distinctive molecular, pathological and clinical characteristics of <i>BRAF</i> -mutant colorectal tumors. Expert Review of Molecular Diagnostics, 2015, 15, 979-987.	3.1	14